GTx

At GTx, They focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body.

Launch date

1997

Market cap

Enterprise valuation

Memphis Tennessee (HQ)

Date	Investors	Amount	Round
Aug 2003	Oracle MB Venture Partners Joseph R. Hyde III	$20.0m	Series E
Feb 2004	N/A	N/A	IPO
2008	N/A	$30.0m	Debt
Jan 2008	N/A	$30.0m	Early VC
Mar 2014	Boxer Capital	$21.3m	Post IPO Equity
Nov 2014	BVF Partners Boxer Capital	$43.4m	Post IPO Equity
Sep 2017	Abingworth Aisling Capital CAM CAPITAL LIMITED Amzak Capital Management Boxer Capital CAM Capital	$48.5m	Post IPO Equity
Total Funding		$50.0m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about GTx